Clinical & Translational Oncology最新文献_第8页

Correction: Assessment of telomerase expression in melanoma and cutaneous squamous cell carcinoma: correlation with clinical parameters. 修正：端粒酶在黑色素瘤和皮肤鳞状细胞癌中的表达评估：与临床参数的相关性。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-01 DOI: 10.1007/s12094-025-03940-y

Tuqa Nasser Alsurhi, Asem Shalaby, Shadia Al-Sinawi, Mohamed Mabruk

引用次数: 0

Frequency and predictors of caregiver burden among patients with cancer receiving palliative cancer treatment. 接受姑息性癌症治疗的癌症患者中照顾者负担的频率和预测因素。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-01 Epub Date: 2025-03-10 DOI: 10.1007/s12094-025-03885-2

Juan Luis Torres-Tenor, Elsa Bernal-Hertfelder, Ana Pertejo-Fernández, Jorge Luis Ramón-Patiño, Andrés Redondo, Alberto Alonso-Babarro, Eduardo Bruera

{"title":"Frequency and predictors of caregiver burden among patients with cancer receiving palliative cancer treatment.","authors":"Juan Luis Torres-Tenor, Elsa Bernal-Hertfelder, Ana Pertejo-Fernández, Jorge Luis Ramón-Patiño, Andrés Redondo, Alberto Alonso-Babarro, Eduardo Bruera","doi":"10.1007/s12094-025-03885-2","DOIUrl":"10.1007/s12094-025-03885-2","url":null,"abstract":"Purpose: Assess the frequency of caregiver burden among patients with advanced cancer receiving palliative anticancer treatment. Compare characteristics of those who show caregiver burden versus those who do not.Methods/patients: This is a cross-sectional study in two university hospital oncology departments. Caregivers completed the Reduced Zarit Burden Interview and Emotional Distress Thermometer. Data were analyzed to identify factors associated with caregiver burden.Results: 79 informal primary caregivers participated, mostly women (65%, N = 51), middle-aged (median 57, SD = 9), employed (54%), and spouses (58%, N = 46). Most had medium economic status (70%, N = 55), no other dependents (51%, N = 40), support from other caregivers (56%, N = 44), and good self-rated health (82%, N = 65). Caregiver burden affected 61% (N = 48), more often women (p = 0.049), those with high stress (p = 0.001), and when more people were involved in patient care (p = 0.048).Conclusions: Caregiver burden is common in informal primary caregivers of patients with advanced cancer receiving palliative treatment, especially in highly stressed women.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3827-3832"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhanced anti-tumor effects of combined electric fields, cabozantinib, and radiation therapy in metastatic renal cell carcinoma. 联合电场、卡博赞替尼和放射治疗对转移性肾细胞癌的抗肿瘤作用增强。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-01 Epub Date: 2025-03-24 DOI: 10.1007/s12094-025-03898-x

Jinju Heo, Yunhui Jo, Myonggeun Yoon

{"title":"Enhanced anti-tumor effects of combined electric fields, cabozantinib, and radiation therapy in metastatic renal cell carcinoma.","authors":"Jinju Heo, Yunhui Jo, Myonggeun Yoon","doi":"10.1007/s12094-025-03898-x","DOIUrl":"10.1007/s12094-025-03898-x","url":null,"abstract":"Purpose: This study aimed to evaluate the therapeutic potential of combining cabozantinib, electric fields (EFs; also called Tumor Treating Fields [TTFields]), and radiation in the treatment of metastatic renal cell carcinoma (RCC), focusing on overcoming resistance to conventional monotherapeutic regimens.Methods: Human renal cancer cell lines (A498, Caki-1) were treated with cabozantinib (10 µM) for at least 6 h, TTFields (200 kHz, 0.8 V/cm) for 24 h, and radiation (3 Gy), both individually and in combination. Cellular responses, including proliferation, apoptosis, and metastatic potential, were analyzed by flow cytometry and Transwell assays.Results: The combination of cabozantinib, TTFields, and radiation exhibited synergistic effects, significantly reducing cell proliferation, enhancing apoptosis, and suppressing metastatic capacity compared with individual treatments. Triple therapy resulted in marked inhibition of metastasis-related markers and changes in apoptotic profiles compared with the control group.Conclusion: This multimodal therapy demonstrated superior efficacy in reducing the metastatic potential and prolonging the survival of RCC cells, offering a promising approach to overcoming treatment resistance in patients with metastatic RCC.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3707-3716"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). 2025年胃食管癌的生物标志物：西班牙医学肿瘤学会（SEOM）和西班牙病理学会（SEAP）的最新共识声明。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-01 Epub Date: 2025-03-12 DOI: 10.1007/s12094-025-03865-6

Maria Alsina Maqueda, Ana Teijo Quintáns, Miriam Cuatrecasas, Maria Jesús Fernández Aceñero, Ana Fernández Montes, Carlos Gómez Martín, Paula Jiménez Fonseca, Carolina Martínez Ciarpaglini, Fernando Rivera Herrero, Mar Iglesias Coma

{"title":"Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).","authors":"Maria Alsina Maqueda, Ana Teijo Quintáns, Miriam Cuatrecasas, Maria Jesús Fernández Aceñero, Ana Fernández Montes, Carlos Gómez Martín, Paula Jiménez Fonseca, Carolina Martínez Ciarpaglini, Fernando Rivera Herrero, Mar Iglesias Coma","doi":"10.1007/s12094-025-03865-6","DOIUrl":"10.1007/s12094-025-03865-6","url":null,"abstract":"Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA. Four key biomarkers are essential for targeted therapy: HER2 overexpression/amplification, deficient mismatch repair/microsatellite instability (dMMR/MSI), PD-L1, and Claudin18.2 expression. Immunohistochemistry is the recommended method for these biomarkers evaluation. In addition, the assessment of biomarkers like FGFR2b is likely to become routine in the near future. Experts from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have formed a consensus to optimize biomarker detection and usage in clinical practice. Their recommendations aim to improve personalized treatment strategies for GEA and ESCC patients, integrating new diagnostic insights into routine care.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3580-3594"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effects of psychological intervention on negative emotions, pain, and sleep in patients with advanced colon cancer. 心理干预对晚期结肠癌患者负面情绪、疼痛和睡眠的影响。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-01 Epub Date: 2025-03-31 DOI: 10.1007/s12094-025-03910-4

Gang Wang, Shengjie Pan

{"title":"The effects of psychological intervention on negative emotions, pain, and sleep in patients with advanced colon cancer.","authors":"Gang Wang, Shengjie Pan","doi":"10.1007/s12094-025-03910-4","DOIUrl":"10.1007/s12094-025-03910-4","url":null,"abstract":"Objective: To investigate the effectiveness of psychological interventions in improving negative emotions, pain, and sleep quality among patients with advanced colon cancer.Methods: From March 2021 to March 2023, a total of 218 patients with advanced colon cancer were selected from the First Affiliated Hospital of Soochow University based on strict inclusion and exclusion criteria. Patients were randomly assigned to either the control group or the observation group (109 patients each) using a random number table. The control group received standard medical care, while the observation group received psychological interventions. Both groups were assessed for anxiety and depression levels [using the Self-Rating Anxiety Scale (SAS) and the Self-Rating Depression Scale (SDS)], sleep quality [measured by the Pittsburgh Sleep Quality Index (PSQI)], pain intensity [using the Visual Analog Scale (VAS)], and overall quality of life. Inter-group comparisons were conducted.Results: Post-intervention assessments showed a decrease in SAS and SDS scores for both groups, with the observation group demonstrating a more significant reduction (P < 0.05). Additionally, the observation group reported significantly lower pain levels (VAS scores) and improved sleep quality (PSQI scores) compared to the control group, along with a markedly higher quality of life as measured by the Quality of Life Core Questionnaire (QLQ-30) (P < 0.05).Conclusion: This study demonstrates that psychological interventions effectively alleviate anxiety, depression, pain, and sleep disturbances in patients with advanced colon cancer, thereby improving their overall quality of life. However, further studies are required to explore the long-term impact on prognosis.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3672-3678"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). 更正：胃食管癌生物标志物2025：西班牙肿瘤医学学会（SEOM）和西班牙病理学会（SEAP）的最新共识声明。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-01 DOI: 10.1007/s12094-025-03941-x

Maria Alsina Maqueda, Ana Teijo Quintáns, Miriam Cuatrecasas, Maria Jesús Fernández Aceñero, Ana Fernández Montes, Carlos Gómez Martín, Paula Jiménez Fonseca, Carolina Martínez Ciarpaglini, Fernando Rivera Herrero, Mar Iglesias Coma

引用次数: 0

Comparison of oncological care in a hospital center before and after the integration of specialized oncology services. 某医院中心整合肿瘤专科服务前后肿瘤护理的比较。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-01 Epub Date: 2025-04-10 DOI: 10.1007/s12094-025-03902-4

C Quero, D Martín-García, F Rivas-Ruiz, M García-Aranda, M Redondo

{"title":"Comparison of oncological care in a hospital center before and after the integration of specialized oncology services.","authors":"C Quero, D Martín-García, F Rivas-Ruiz, M García-Aranda, M Redondo","doi":"10.1007/s12094-025-03902-4","DOIUrl":"10.1007/s12094-025-03902-4","url":null,"abstract":"Background: Cancer represents a continuous challenge for global public health, with steadily increasing incidence and mortality rates.Methods: This manuscript presents a comprehensive and retrospective analysis of oncological care in a hospital, evaluating quality indicators after the introduction of a specialized oncology service at the center. Initially, it was implemented partially and then fully, allowing for the comparison of three different periods: without service, with partial service, and with full service. The data used was obtained from the TumorRegistry of the Costa del Sol Hospital (HTRCSH).Results: Throughout this study, significant improvements were identified in various indicators, such as a reduction in the percentage of patients admitted through the emergency service (p=0.001), the percentage of primary cancers of unknown origin (p=0.006), and the percentage of cancers with regional extension (p=0.004). Additionally, there was a notable increase in the percentage of inclusion of the complete tumor stage information in the patient's medical record (p=0.004), the percentage of patients receiving adjuvant treatment (p=0.001), and the percentage of patients with an intention for radical treatment (p=0.007).Conclusions: These results underscore the importance of oncology services in improving care for cancer patients. Despite the limitations, our study highlights important areas for future research, which will be addressed through additional data collection and more detailed analyses.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3811-3818"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of extracellular vesicles in colorectal cancer: a systematic review and meta-analysis. 结直肠癌细胞外囊泡的预后价值：一项系统综述和荟萃分析。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-01 Epub Date: 2025-04-09 DOI: 10.1007/s12094-025-03915-z

Haodong Zhang, Bohan Wu, Tingting Zhou, Liaoqiong Fang

{"title":"Prognostic value of extracellular vesicles in colorectal cancer: a systematic review and meta-analysis.","authors":"Haodong Zhang, Bohan Wu, Tingting Zhou, Liaoqiong Fang","doi":"10.1007/s12094-025-03915-z","DOIUrl":"10.1007/s12094-025-03915-z","url":null,"abstract":"Objective: Extracellular vesicles (EVs) are prognostic factors in colorectal cancer (CRC). This study aims to evaluate the prognostic value of EVs CRC.Methods: Clinical studies that directly investigated the association between EVs in different kinds of body fluids of CRC patients and patient prognosis were included by searching the PubMed, Web of Science, ClinicalTrials, and CENTRAL databases. The associations between single biomarkers, molecular panels, and EVs count with overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) were analyzed. Heterogeneity was assessed using the I2 statistic, with a random-effects model applied when I2 > 30% and a fixed-effects model when I2 ≤ 30%.Results: A total of 56 studies involving 5,985 patients were included. All included studies detected EVs in blood. Univariate analysis revealed an association between EVs single-biomarkers and OS (pHR = 2.07, 95% CI: 1.73-2.73) and DFS (pHR = 2.20, 95% CI: 1.46-2.79). Additionally, univariate analysis revealed an association between molecular-panels in EVs and OS (pHR = 3.67, 95% CI: 2.51-5.36) and RFS (pHR = 3.97, 95% CI: 1.57-10.08). Moreover, an association was observed between a EVs count and OS (pHR = 1.87, 95% CI: 1.40-2.49). On the basis of the results of the meta-regression and subgroup analyses, the subgroups of EVs and the disease stage of CRC patients are key factors contributing to the heterogeneity in the associations between EVs single-biomarkers and OS.Conclusion: This study provides compelling evidence that EVs from blood hold prognostic value in CRC.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3687-3700"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prediction of lymph node metastasis in stage I-III colon cancer patients younger than 40 years. 40岁以下I-III期结肠癌患者淋巴结转移的预测。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-01 Epub Date: 2025-04-12 DOI: 10.1007/s12094-025-03903-3

Wei-Hao Zhang, Meng-Di Huang, Yan-Ling Tu, Kun-Zhai Huang, Chao-Jun Wang, Zhao-Hui Liu, Rui-Sheng Ke

{"title":"Prediction of lymph node metastasis in stage I-III colon cancer patients younger than 40 years.","authors":"Wei-Hao Zhang, Meng-Di Huang, Yan-Ling Tu, Kun-Zhai Huang, Chao-Jun Wang, Zhao-Hui Liu, Rui-Sheng Ke","doi":"10.1007/s12094-025-03903-3","DOIUrl":"10.1007/s12094-025-03903-3","url":null,"abstract":"Aims: Developing a clinical model to predict the individual risk of lymph node metastasis (LNM) in young colon cancer (CC) patients may address an unmet clinical need.Methods: A total of 2,360 CC patients under 40 years old were extracted from the SEER database and randomly divided into development and validation cohorts. Risk factors for LNM were identified by using a logistic regression model. A weighted scoring system was built according to beta coefficients (β) calculated by a logistic regression model. Model discrimination was evaluated by C-statistics, model calibration was evaluated by H-L test and calibration plot.Results: Risk factors were identified as T stage, tumor site, grade and histology. The area under the receiver operating characteristic curve (AUC-ROC) was 0.66 in both cohorts, indicating acceptable discriminatory power. The H-L test showed good calibration in the development cohort (χ2=2.869, P=0.837) and validation cohort (χ2=10.103, P=0.120) which also had been proved by calibration plot. Patients with total risk score of 0-1, 2-3 and 4-6 were considered as low, medium and high risk group.Conclusion: This clinical risk prediction model is accurate enough to identify young CC patients with high risk of LNM and can further provide individualized clinical reference.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3679-3686"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive clinico-pathological review of a series of pediatric, adolescents and young adults with high-grade osteosarcoma: from clinics to biomarker discovery. 一系列儿童、青少年和年轻成人高级别骨肉瘤的综合临床病理回顾：从临床到生物标志物的发现。

IF 2.5 3区医学

Clinical & Translational Oncology Pub Date : 2025-09-01 Epub Date: 2025-04-08 DOI: 10.1007/s12094-025-03901-5

Susana Buendía-López, Alba Rubio-San-Simón, Jen-Hao Wu, Daniel Azorín-Cuadrillero, Ana Sanz-Miguel, Álvaro Lassaletta, Sara Inmaculada Sirvent-Cerdá, Laura Rey-Portela, Juan Carlos Abril, Lucas Moreno, Luis Madero-López, Javier García-Castro, Francisco Bautista

{"title":"A comprehensive clinico-pathological review of a series of pediatric, adolescents and young adults with high-grade osteosarcoma: from clinics to biomarker discovery.","authors":"Susana Buendía-López, Alba Rubio-San-Simón, Jen-Hao Wu, Daniel Azorín-Cuadrillero, Ana Sanz-Miguel, Álvaro Lassaletta, Sara Inmaculada Sirvent-Cerdá, Laura Rey-Portela, Juan Carlos Abril, Lucas Moreno, Luis Madero-López, Javier García-Castro, Francisco Bautista","doi":"10.1007/s12094-025-03901-5","DOIUrl":"10.1007/s12094-025-03901-5","url":null,"abstract":"Background: We analyzed clinical and immunohistochemical characteristics of pediatric, adolescents and young adults with high-grade osteosarcoma (HGOS) to validate prognostic factors, identify targetable and prognostic biomarkers and define management of multiple relapses.Methods: Retrospective analysis of 67 patients with HGOS between 2001 and 2020 was studied. BTN3A2, HSP90 and GLYPICAN1 were further analyzed based on their high expression on in silico model.Results: Conventional osteosarcoma was the most frequent histology subtype (89.5%); 26.9% of patients had metastases at diagnosis. Proportion of limb-sparing surgery and R0 resection increased before and after 2011 (66.6% vs. 96.2%; 78.5% vs 87.5% respectively), while no treatment-related deaths occurred after 2011. 5-year OS and EFS were 61% and 56.6%, (5.4-year median follow-up (0.20-17.40). In multivariate analysis, metastatic disease was the sole independent prognostic factor. 5-year EFS and OS for patients with 1st, 2nd, and 3rd relapse were 8-12%, 0-5%, and 11.1-11.1% respectively. BTN3A2 was highly expressed at diagnosis, surgery, and relapse.Conclusion: Metastatic disease remains the most important prognosis factor in HGOS. Improvements in surgical procedures and reduction in treatment-related mortality were observed. Survival after multiple relapses remains poor; we define figures to be used for benchmarking in clinical trials. BTN3A2 is a potential therapeutic target.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3781-3792"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0